Paradromics

Paradromics is a clinical-stage medical device company pioneering a high-bandwidth, scalable brain-computer interface platform. The company's core technology focuses on high-channel-count, single-neuron recording combined with advanced AI decoding algorithms, with an initial application targeting speech restoration. Having received FDA Breakthrough Device Designation and IDE approval, Paradromics is advancing its lead product, Connexus BCI, into clinical studies, positioning it as a key player in the competitive neuroprosthetics landscape. The company blends deep technical expertise from academia and DARPA with seasoned medical device leadership to navigate the complex path to commercialization.

High-data-rate, fully implantable brain-computer interface (BCI) platform featuring scalable, modular implants capable of recording from over 1,600 intracortical channels (single neurons). The platform integrates advanced AI and machine learning algorithms to decode massive neural datasets in real-time for therapeutic applications.

Paradromics operates in a competitive neuroprosthetics field with players like Synchron (endovascular stent-electrode), Blackrock Neurotech (established pedestal-based systems), and Neuralink (high-channel-count, robotic implantation). Paradromics differentiates by emphasizing ultra-high channel count from a fully implantable system and a specific initial focus on speech decoding, competing on raw data bandwidth and potential decoding fidelity.